CEO: Paul G. Higham
Wellington contacts:
Erich Schlick
Thomas Widmann
| Activate the self defense mechanisms of the human body |
immatics is developing peptide-based therapeutic cancer vaccines, i.e. drugs that help to activate the immune system of the patient to successfully fight cancer diseases. The company's goal is to create highly specific and highly tolerable therapeutics against various cancers on the basis of its proprietary drug discovery technology. immatics is in clinical phase 2 trials for its product candidates IMA901 against renal cancer and IMA 910 against colorectal cancer, and has further product candidates for the treatment of glioblastoma and gastric cancer in earlier stages of development. In January 2008, the company opened an office in Martinsried, near Munich, one of the largest biotech clusters in Europe.
First investment: February 2004
immatics biotechnologies GmbH
Paul-Ehrlich-Str. 15
72076 Tuebingen
Germany
